VetoquinolVetoquinol
France · FR0004186856 · reports in EUR · Europe
The answers
From the annual report for the year to Dec 31, 2025. Each line says what it is based on.
- Is it growing?Fair
- Revenue −2.5% in the year to Dec 31, 2025, on the year before.
- Is it a good business?Fair
- It earned 9.7% on its shareholders' equity in the year to Dec 31, 2025.
- Is it safe?Good
- Equity is 77% of its assets, and operations brought in cash in the year.
- Is the price fair?n/a
- Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.
The year
Year to Dec 31, 2025, consolidated, in EUR.
revenue
operating margin
net profit
Year by year
As filed; an earlier year can differ from its own report when the company restated it.
| Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | |
|---|---|---|---|---|
| Revenue | €540M | €529M | €539M | €526M |
| Operating profit | €74M | €74M | €77M | €78M |
| Net profit to shareholders | €48M | €56M | €59M | €57M |
| Earnings per share | €4.06 | €4.70 | €4.98 | €4.94 |
| Cash from operations | €63M | €89M | €86M | €72M |
| Capital spending | €17M | €15M | €15M | €17M |
| Cash | €94M | €147M | €206M | €221M |
| Total assets | €652M | €692M | €744M | €764M |
| Equity | €485M | €527M | €576M | €591M |
What they do
In the company's own words, from the annual report.
6.5.2 Événements significatifs 6.5.2.1 Effort de R & D En 2025, le Groupe a maintenu son effort de R & D ; il ressort à 7,9 % du CA (2024 : 8,1 %) reflétant ainsi sa volonté d'accroître les dépenses de R & D pour soutenir l'innovation.
Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the answers and ratios from the filed figures.